Table 3—

Relative concentration of bronchoalveolar lavage fluid (BALF) oxidation markers and antioxidants

ControlARDS all patientsPrimary ARDSSecondary ARDS
GSSG/PL M/M0.001±0.0010.006±0.002***0.006±0.002**0.005±0.002**
F2-isoprostanes/PL M/M×1060.79±0.183.36±0.62***3.59±0.77**2.66±0.98**
GSH/PL M/M0.05±0.010.11±0.040.13±0.050.05±0.02
Ascorbic acid/PL M/M0.013±0.0010.096±0.027**0.105±0.034**0.065±0.020**
Uric acid/PL M/M0.020±0.0020.384±0.067***0.393±0.079***0.352±0.128***
α-Tocopherol/PL M/M×1030.65±0.062.04±0.23***2.28±0.26***1.22±0.34
Retinol/PL M/M×1030.14±0.040.75±0.13***0.81±0.17***0.58±0.15***
Plasmalogens/PL %1.07±0.040.68±0.05***0.63±0.06***0.72±0.07***
PUFA/total FA %7.19±0.2920.70±1.39***20.06±1.96***21.09±1.94***

  • Data are presented as mean±sem. The relative (compared with total BALF phospholipids (PL)) concentrations of oxidised glutathione (GSSG), F2-isoprostanes, reduced glutathione (GSH), vitamins C (ascorbic acid), E (α-tocopherol) and A (retinol), and uric acid are given. Plasmalogens and polyunsaturated fatty acids (PUFA) are given as percent (weight/weight) of total phospholipids or total fatty acids (FA) in BALF. Acute respiratory distress syndrome (ARDS) patients were further divided into primary and secondary ARDS. **: p<0.01; ***: p<0.001 compared with controls